Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Enanta Pharmaceuticals (ENTA) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Q3 2025 value amounting to $33.5 million.

  • Enanta Pharmaceuticals' Operating Expenses fell 2462.83% to $33.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $150.7 million, marking a year-over-year decrease of 2041.61%. This contributed to the annual value of $150.7 million for FY2025, which is 2041.61% down from last year.
  • As of Q3 2025, Enanta Pharmaceuticals' Operating Expenses stood at $33.5 million, which was down 2462.83% from $37.2 million recorded in Q2 2025.
  • Enanta Pharmaceuticals' Operating Expenses' 5-year high stood at $58.1 million during Q4 2021, with a 5-year trough of $33.5 million in Q3 2025.
  • In the last 5 years, Enanta Pharmaceuticals' Operating Expenses had a median value of $50.0 million in 2023 and averaged $48.9 million.
  • As far as peak fluctuations go, Enanta Pharmaceuticals' Operating Expenses skyrocketed by 3364.9% in 2021, and later crashed by 2462.83% in 2025.
  • Quarter analysis of 5 years shows Enanta Pharmaceuticals' Operating Expenses stood at $58.1 million in 2021, then dropped by 7.68% to $53.6 million in 2022, then decreased by 1.32% to $52.9 million in 2023, then decreased by 23.42% to $40.5 million in 2024, then fell by 17.26% to $33.5 million in 2025.
  • Its last three reported values are $33.5 million in Q3 2025, $37.2 million for Q2 2025, and $39.5 million during Q1 2025.